Trump's inauguration fund receives a $1 million donation from Hims & Hers.

• On Tuesday, CNBC reported that President-elect Donald Trump's inauguration fund received a $1 million donation from Hims & Hers Health.
• The company is among the tech organizations that have recently attempted to win over the incoming administration.
• Last year, Hims & Hers gained significant recognition in the digital health industry due to the success of its new weight loss product.

CNBC confirmed Tuesday that $1 million has been donated to President-elect Donald Trump's inauguration fund.

The tech company that provides direct-to-consumer treatments for various conditions, such as weight loss, erectile dysfunction, and hair loss, is the latest in a series of tech companies that have attempted to win the favor of the incoming administration. Both OpenAI CEO Sam Altman and CEO Tim Cook have reportedly made $1 million donations to the inaugural fund, while CEO Sam Altman and CEO Tim Cook have also made $1 million donations to the inaugural fund.

The company stated in a CNBC interview that they support leaders and advocates who are dedicated to reforming America's flawed healthcare system.

Axios first reported Hims & Hers' donation.

Last year, Hims & Hers gained prominence in the digital health industry due to the success of its new weight loss product.

In May, the company started offering compounded semaglutide through its platform after launching a weight loss program in late 2023. Semaglutide is the active ingredient in Novo Nordisk's blockbuster medications Ozempic and Wegovy, which can cost around $1,000 a month without insurance. Compounded semaglutide is a cheaper, custom-made alternative to the brand drugs and can be produced when the brand-name treatments are in shortage.

The future of compounded GLP-1s in the U.S. is uncertain due to conflicting opinions about the drugs from members of Trump's circle, including Robert F. Kennedy Jr., Trump's pick to lead the Department of Health and Human Services, who has criticized GLP-1s and suggested that lifestyle changes should be the first line of response to obesity, while acknowledging that GLP drugs have a place.

Dr. Marty Makary, Trump's nominee for the Food and Drug Administration, has been an executive at Sesame, a telehealth company that connects patients to physicians who can prescribe compounded GLP-1s. However, Makary's role at Sesame has been mostly ceremonial in recent years.

Elon Musk, Trump's close confidant and CEO, has publicly endorsed the use of medications.

Making GLP inhibitors super low cost to the public would greatly enhance the health, lifespan, and quality of life for Americans, as stated by Musk on X in December.

In a late-year event in New York City with reporters in attendance, including CNBC, Hims & Hers announced its intention to collaborate with the incoming administration and advocate for the worth of medications.